DK0830130T3 - TNF-alfa-omdannende enzym - Google Patents

TNF-alfa-omdannende enzym

Info

Publication number
DK0830130T3
DK0830130T3 DK96923209T DK96923209T DK0830130T3 DK 0830130 T3 DK0830130 T3 DK 0830130T3 DK 96923209 T DK96923209 T DK 96923209T DK 96923209 T DK96923209 T DK 96923209T DK 0830130 T3 DK0830130 T3 DK 0830130T3
Authority
DK
Denmark
Prior art keywords
converting enzyme
tnf alpha
protease
alpha converting
isolated
Prior art date
Application number
DK96923209T
Other languages
English (en)
Inventor
Roy A Black
Charles Rauch
Carl J March
Douglas P Cerretti
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,345 external-priority patent/US5830742A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0830130T3 publication Critical patent/DK0830130T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
DK96923209T 1995-06-08 1996-06-03 TNF-alfa-omdannende enzym DK0830130T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48245895A 1995-06-08 1995-06-08
US50461495A 1995-07-20 1995-07-20
US08/655,345 US5830742A (en) 1995-06-08 1996-05-23 TNF-α converting enzyme
PCT/US1996/008407 WO1996041624A1 (en) 1995-06-08 1996-06-03 TNF-α CONVERTING ENZYME

Publications (1)

Publication Number Publication Date
DK0830130T3 true DK0830130T3 (da) 2004-12-20

Family

ID=27413615

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96923209T DK0830130T3 (da) 1995-06-08 1996-06-03 TNF-alfa-omdannende enzym

Country Status (13)

Country Link
EP (1) EP0830130B9 (da)
JP (1) JP4326022B2 (da)
AT (1) ATE274346T1 (da)
AU (1) AU712759C (da)
CA (1) CA2222650C (da)
DE (1) DE69633231T2 (da)
DK (1) DK0830130T3 (da)
ES (1) ES2227598T3 (da)
IL (1) IL122305A0 (da)
NO (1) NO323623B1 (da)
NZ (2) NZ510390A (da)
PT (1) PT830130E (da)
WO (1) WO1996041624A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase
AU3514997A (en) * 1996-07-12 1998-02-09 Schering Corporation Mammalian tnf-alpha convertases
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6046031A (en) 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
WO1998037092A2 (en) * 1997-02-25 1998-08-27 The Procter & Gamble Company Use of a novel disintegrin metalloprotease
US6551857B2 (en) 1997-04-04 2003-04-22 Elm Technology Corporation Three dimensional structure integrated circuits
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
ATE366303T1 (de) * 1998-02-04 2007-07-15 Immunex Corp Kristallines tnf-alpha-konvertierendes enzym und verwendung davon
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (en) 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
WO2005030798A2 (en) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services TNFαCONVERTING ENZYME INHIBITORY AGENTS AND STIMULATORY AGENTS-
WO2008025748A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-containing proteins
AU2007291282B2 (en) * 2006-08-28 2011-10-20 Ares Trading S.A. Process for the purification of Fc-fusion proteins
CA2825990A1 (en) 2011-02-01 2012-08-09 Cancer Research Technology Limited Anti-tace antibody molecules and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189682T1 (de) * 1989-08-16 2000-02-15 Chiron Corp Prohormonspaltungsplatzblockierungsantikörper
DE69029970T2 (de) * 1989-08-16 1997-06-19 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
EP0535059B1 (de) * 1990-06-22 1995-11-29 Jens LÜDEMANN Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände
DE69132470D1 (de) * 1990-08-06 2000-12-21 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
WO1995024501A1 (en) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
CA2249985A1 (en) * 1996-03-26 1997-10-02 Glaxo Group Limited Tumour necrosis factor alpha convertase

Also Published As

Publication number Publication date
DE69633231T2 (de) 2005-08-04
EP0830130B9 (en) 2004-12-29
CA2222650C (en) 2009-10-13
NO975438L (no) 1998-02-06
ES2227598T3 (es) 2005-04-01
EP0830130B1 (en) 2004-08-25
EP0830130A1 (en) 1998-03-25
NZ510390A (en) 2002-11-26
IL122305A0 (en) 1998-04-05
NO323623B1 (no) 2007-06-18
PT830130E (pt) 2004-11-30
NZ312285A (en) 2001-04-27
MX9709744A (es) 1998-07-31
AU712759C (en) 2001-08-09
WO1996041624A1 (en) 1996-12-27
NO975438D0 (no) 1997-11-26
EP0830130A4 (en) 2000-03-29
DE69633231D1 (de) 2004-09-30
AU712759B2 (en) 1999-11-18
AU6378196A (en) 1997-01-09
CA2222650A1 (en) 1996-12-27
ATE274346T1 (de) 2004-09-15
JP4326022B2 (ja) 2009-09-02
JP2002515020A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
DK0830130T3 (da) TNF-alfa-omdannende enzym
Wachtfogel et al. Structural biology, cellular interactions and pathophysiology of the contact system
UY27972A1 (es) Derivados de hidantoína
TR199802694T2 (xx) IL-8 resept�r kar��tlar�
DE69833654D1 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
ATE267168T1 (de) Beta-alanin-derivate als zell-adhäsions- inhibitoren
DE69825904D1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
TR199802695T2 (xx) IL-8 Resept�r kar��tlar�
LV10652A (lv) Jauni proteolitiskie fermenti un to izmantosana mazgasanas lidzeklos
EA199800119A1 (ru) Ингибиторы адгезии клеток
ATE199090T1 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
TR200101899T2 (tr) Trombin inhibitörleri.
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
DE69625506D1 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
DE69732985D1 (de) Verfahren der zelloberflächenaktivierung und -hemmung
DK0869970T3 (da) Endothelcelleprolifereringsinhibitor og dens anvendelse
DE69737500D1 (de) Von willebrand-faktor multimerase
ES2171563T3 (es) Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
ATE282089T1 (de) Inhibitorresistente serinproteasen
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
MA26540A1 (fr) Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
ATE238062T1 (de) Hemmung von hiv-infektion
BR9608978A (pt) Inibidor de protease de serina derivado de imidazo [1,5a] piridina composição farmacêutica e utilização do inibidor de protease
Hsu et al. Elastase activity in granulomatous inflammation in experimental murine leprosy
DE60220185D1 (de) Screening-verfahren für substanzen zur behandlung von diabetes